The Cost of Drug Regulation

Economist Sam Peltzman discusses the high costs and delayed innovation caused by the current drug regulation process. He argues that the delay in bringing new drugs to market not only burdens drug companies, but also deprives potential users of potentially life-saving treatments. Peltzman's research suggests that the current regulatory system may actually be causing more harm than good.